Clinical Trial Detail

NCT ID NCT04385368
Title Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Age Groups: adult senior

Additional content available in CKB BOOST